AQR Capital Management LLC Purchases 59,361 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• AQR Capital Management LLC increased its stake in Medpace Holdings, Inc. by 12.4% during Q1, acquiring an additional 59,361 shares for a total of 539,547 shares.
• Company executives have recently sold shares, with VP Susan E. Burwig and CEO August J. Troendle selling a total of 43,696 shares worth over $20 million combined in July and August.
• Medpace reported a strong quarter with an EPS of $3.10, beating estimates, and a revenue increase of 14.2% compared to the previous year.

AQR Capital Management LLC grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 12.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 539,547 shares of the company's stock after purchasing an additional 59,361 shares during the quarter. AQR Capital Management LLC owned approximately 1.88% of Medpace worth $158,470,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Brooklyn Investment Group raised its position in shares of Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares during the period. Whittier Trust Co. increased its position in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after acquiring an additional 35 shares during the period. Colonial Trust Co SC increased its position in Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after acquiring an additional 105 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in Medpace during the first quarter worth $60,000. Finally, Assetmark Inc. increased its position in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after acquiring an additional 43 shares during the period. Institutional investors own 77.98% of the company's stock.

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 7,500 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.14, for a total value of $3,376,050.00. Following the sale, the vice president owned 57,500 shares in the company, valued at approximately $25,883,050. The trade was a 11.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 36,196 shares of the business's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the completion of the sale, the chief executive officer owned 925,799 shares in the company, valued at $440,587,744.10. This represents a 3.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 151,266 shares of company stock worth $69,311,427 in the last three months. Company insiders own 20.30% of the company's stock.

Medpace Price Performance

MEDP opened at $481.23 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The firm's fifty day moving average price is $405.65 and its two-hundred day moving average price is $342.20. The company has a market capitalization of $13.52 billion, a P/E ratio of 35.78, a P/E/G ratio of 2.99 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter in the previous year, the company earned $2.75 EPS. The firm's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research reports. Mizuho boosted their target price on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Barclays boosted their target price on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Truist Financial boosted their target price on shares of Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Finally, TD Cowen reaffirmed a "sell" rating and set a $366.00 target price (up previously from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Reduce" and an average target price of $412.73.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.